Extrapolating Survival From Randomized Clinical Trial Data-Possibilities and Caution

Comment

. 2021 Nov 1;6(11):1305-1307.

doi: 10.1001/jamacardio.2021.2629.

Laine Elliott Thomas^{1

2

3}, Ann Marie Navar^{4

5}, Michael J Pencina^{1

2

3}

Affiliations

¹ Department of Biostatistics and Bioinformatics, Duke University, Durham, North Carolina.
² Duke Clinical Research Institute, Durham, North Carolina.
³ Associate Editor for Statistics, JAMA Cardiology.
⁴ Department of Cardiology, University of Texas Southwestern Medical School, Dallas.
⁵ Associate Editor, JAMA Cardiology.

Comment

Laine Elliott Thomas et al. JAMA Cardiol. 2021.

. 2021 Nov 1;6(11):1305-1307.

doi: 10.1001/jamacardio.2021.2629.

Laine Elliott Thomas^{1

2

3}, Ann Marie Navar^{4

5}, Michael J Pencina^{1

2

3}

¹ Department of Biostatistics and Bioinformatics, Duke University, Durham, North Carolina.
² Duke Clinical Research Institute, Durham, North Carolina.
³ Associate Editor for Statistics, JAMA Cardiology.
⁴ Department of Cardiology, University of Texas Southwestern Medical School, Dallas.
⁵ Associate Editor, JAMA Cardiology.

No abstract available

Comment on

Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis of a Phase 3 Randomized Clinical Trial.
Docherty KF, Jhund PS, Claggett B, Ferreira JP, Bengtsson O, Inzucchi SE, Køber L, Kosiborod MN, Langkilde AM, Martinez FA, Ponikowski P, Sabatine MS, Sjöstrand M, Solomon SD, McMurray JJV; DAPA-HF Investigators and Committees. Docherty KF, et al. JAMA Cardiol. 2021 Nov 1;6(11):1298-1305. doi: 10.1001/jamacardio.2021.2632. JAMA Cardiol. 2021. PMID: 34319398 Free PMC article. Clinical Trial.